Takeda Pharmaceutical (NYSE:TAK) Reaches New 12-Month High - Time to Buy?

Key Points

• Takeda Pharmaceutical's shares reached a new 52-week high of $15.56 during trading, with the latest price recorded at $15.50.
• The company reported earnings of $0.52 per share, exceeding analyst expectations of $0.47, but fell short on revenue with $7.45 billion against a $7.96 billion estimate.
• Institutional investors such as JPMorgan Chase and Russell Investments have significantly increased their stakes in Takeda Pharmaceutical, indicating growing confidence in the stock.

Takeda Pharmaceutical Co. (NYSE:TAK - Get Free Report)'s share price hit a new 52-week high during mid-day trading on Wednesday . The company traded as high as $15.56 and last traded at $15.50, with a volume of 711159 shares. The stock had previously closed at $15.20.

Analyst Ratings Changes

Separately, Zacks Research downgraded shares of Takeda Pharmaceutical from a "hold" rating to a "strong sell" rating in a research report on Thursday. One research analyst has rated the stock with a Buy rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, the company has an average rating of "Hold".

Takeda Pharmaceutical Stock Down 2.8%

The company has a debt-to-equity ratio of 0.60, a current ratio of 1.16 and a quick ratio of 0.59. The firm has a 50-day simple moving average of $14.80 and a two-hundred day simple moving average of $14.69. The company has a market cap of $47.98 billion, a PE ratio of 50.27 and a beta of 0.22.

Takeda Pharmaceutical (NYSE:TAK - Get Free Report) last released its quarterly earnings results on Wednesday, July 30th. The company reported $0.52 earnings per share for the quarter, topping the consensus estimate of $0.47 by $0.05. Takeda Pharmaceutical had a return on equity of 10.50% and a net margin of 3.20%.The company had revenue of $7.45 billion during the quarter, compared to the consensus estimate of $7.96 billion. Takeda Pharmaceutical has set its FY 2025 guidance at 3.360-3.360 EPS. Research analysts anticipate that Takeda Pharmaceutical Co. will post 1.64 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Large investors have recently modified their holdings of the stock. Twin Peaks Wealth Advisors LLC purchased a new position in shares of Takeda Pharmaceutical during the 2nd quarter worth about $28,000. FNY Investment Advisers LLC acquired a new position in Takeda Pharmaceutical in the first quarter valued at $37,000. Evelyn Partners Investment Management LLP boosted its holdings in Takeda Pharmaceutical by 163.4% in the second quarter. Evelyn Partners Investment Management LLP now owns 2,515 shares of the company's stock valued at $39,000 after acquiring an additional 1,560 shares during the last quarter. NewSquare Capital LLC boosted its holdings in Takeda Pharmaceutical by 182.4% in the second quarter. NewSquare Capital LLC now owns 3,451 shares of the company's stock valued at $53,000 after acquiring an additional 2,229 shares during the last quarter. Finally, Northwestern Mutual Wealth Management Co. boosted its holdings in Takeda Pharmaceutical by 56.3% in the second quarter. Northwestern Mutual Wealth Management Co. now owns 3,586 shares of the company's stock valued at $55,000 after acquiring an additional 1,292 shares during the last quarter. 9.17% of the stock is currently owned by hedge funds and other institutional investors.

About Takeda Pharmaceutical

Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products in Japan and internationally. It offers pharmaceutical products in the areas of gastroenterology, rare diseases, plasma derived therapies, immunology, oncology, and neuroscience.